OPEN Foundation

OPEN Foundation

Prehistorisch paddenstoelen gebruik in Spanje

paddos_spain508

Europeanen gebruikten 6000 jaar geleden mogelijk paddo’s om religieuze rituelen te verlevendigen. Dat suggereert een grotschildering in Spanje, welke mogelijk paddestoelen met hallucinogene eigenschappen afbeelt—het oudste bewijs van hun gebruik in Europa.

De Selva Pascuala muurschildering, in een grot nabij het dorp Villar del Humo, wordt gedomineerd door een stier. Het is echter een rij van dertien paddestoel-achtige objecten die de interesse wekten van Brian Akers van het Pasco-Hernando Community College in New Port Richey, Florida, en Gaston Guzman van het Ecological Institute of Xalapa in Mexico. Zij denken dat de objecten de fungi Psilocybe hispanica zijn, een lokale soort met hallucinogene eigenschappen.

Net als de objecten die afgebeeld zijn in de muurschildering, heeft P. hispanica een belvormige hoed bekroond met een koepel, en mist hij een annulus—een ring rond de stengel. “Zijn stengels variëren ook van recht tot kronkelig, net zoals in de muurschildering,” zegt Akers.

Dit is echter niet de oudste prehistorische tekening waarvan vermoed wordt dat ze paddo’s afbeeldt. Een Algerijnse muurschildering die mogelijk de soort Psilocybe mairei toont, is 7000 tot 9000 jaar oud.

Lees Akers’ publicatie A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms? voor meer informatie.

Prehistoric mushroom use in Spain

paddos_spain508

Europeans may have used magic mushrooms to liven up religious rituals 6000 years ago. So suggests a cave mural in Spain, which may depict fungi with hallucinogenic properties – the oldest evidence of their use in Europe.

The Selva Pascuala mural, in a cave near the town of Villar del Humo, is dominated by a bull. But it is a row of 13 small mushroom-like objects that interests Brian Akers at Pasco-Hernando Community College in New Port Richey, Florida, and Gaston Guzman at the Ecological Institute of Xalapa in Mexico. They believe that the objects are the fungi Psilocybe hispanica, a local species with hallucinogenic properties.

Like the objects depicted in the mural, P. hispanica has a bell-shaped cap topped with a dome, and lacks an annulus – a ring around the stalk. “Its stalks also vary from straight to sinuous, as they do in the mural,” says Akers.

This isn’t the oldest prehistoric painting thought to depict magic mushrooms, though. An Algerian mural that may show the species Psilocybe mairei is 7000 to 9000 years old.

Read Akers’ publication A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms? for more information.

The Ethnopharmacology of Ayahuasca

EthnopharmacologyayahuascaEthnopharmacology is a relatively new science that studies the cultural aspects of substances (plants, animals, minerals) and their biological characteristics and activities. While investigating and identifying compounds and the various uses they have in indigenous and non-indigenous groups, this science is also involved in studying the bio-activity of these materials. Ethnopharmacology is connected with other ethno-sciences, especially ethnobotany, which studies the uses of plants by human groups and their chemical and biological aspects. Plant development is part of nature but also part of the human culture, since man has been selecting plant materials from millennia for their qualities and characteristics. Humans use plants to eat, to hunt, to build houses, for killing, and from the rich variety of uses man had been given to plants, some kinds of uses involves the magical. Ayahuasca, a psychoactive Amazonian plant preparation, had been and still is used within the context of the sacred, the religious, the divinatory and the therapeutic. Ayahuasca is an excellent bio-active material to be investigated from an ethnopharmacological point of view, since its various uses, in the past and in the present, by many different human groups and for a high diversity of objectives, warrant an interdisciplinary approach. Although many human groups have been using different kinds of flora for reaching and connecting with the sacred, the hallucinogenic botany seems to occupy a very special place in some cultures. The high relevance of these substances is evident in many human groups. In the present book, several authors present to us some of the uses that ayahuasca had and still has in indigenous, mestizo and urban groups. Also, other chapters illustrate the various uses that ayahuasca have in modern science. This pan-Amazonian brew is used actually not only in Brazil, Colombia, Peru or Ecuador, where indigenous groups have been using this plant preparation for centuries, but in North America, Europe and Asia, where non-indigenous groups have been using this brew for many years now. It is an attempt of the present work to try to show the rich diversity that exists around ayahuasca. Because ethnopharmacology involves social aspects of bio-active compounds, the two first articles of the book are made considering the anthropological, cultural and social aspects of ayahuasca. In the first article, Luis Eduardo Luna shows how ayahuasca is used by indigenous and mestizo populations and in the second article Sandra Lucia Goulart discusses the context of the Brazilian ayahuasca religions. Luna and Goulart illustrate the diversity of concepts and ideas that these groups have regarding ayahuasca, discuss concepts and practices of healing and disease in these groups, and compare the ways in which ayahuasca is experienced and explained in these groups. The next articles are about pharmacological aspects of ayahuasca, to complement the social and cultural aspects. On the third article, José Carlos Bouso and Jordi Riba describe the pharmacological and neuropsychiatric aspects of this Amazonian brew. Their work is based in many years of clinical trials with acute ayahuasca administration to healthy volunteers and also on the investigations regarding the possible consequences of the long term consumption of this centenary potion. On the fourth article, Paulo César Ribeiro Barbosa illustrates a case report of a person that has taken ayahuasca for the first time. The possible therapeutic effects of ayahuasca are investigated in the context of the acute and post-acute effects of the brew. On the fifth article, Flávia de Lima Osório and collaborators explore the therapeutic potentials of one of the main ayahuasca alkaloids – harmine – for the treatment of depression, and they also discuss the curative potentials of the brew itself in this psychological disequilibrium. Still on the pharmacological perspective, but also involving psychiatry, the last two articles talk about the possible interactions of ayahuasca and cannabis in humans. One of the articles, which was wrote by me, is a theoretical overview of the eventual interactions – positive, neutral, or negative – that can potentially happen when humans take ayahuasca and cannabis together. The last article, wrote by me and Rick J. Strassman, shows a case report of a young man that had psychotic episodes related directly to the consumption of ayahuasca and cannabis. It is the main intention of the present book to make accurate and easy information regarding as many as possible aspects of ayahuasca accessible to the public. It is hoped that this little book will bring light to an issue that, in many cases, is still debated in obscurity.

The Ethnopharmacology of Ayahuasca, door Rafael Guimarães dos Santos, Transworld Research Network, 99 pagina’s.

Dit boek kunt u op 3 manieren lezen:

    • Door hier de individuele PDFs van elk hoofdstuk te downmloaden.
    • Door het hier als een tijdschrift te lezen.
    • Door het hele bestand hier te lezen.

The Shulgin Index: v. 1: Psychedelic Phenethylamines and Related Compounds

shulgin_indexThe Shulgin Index is a comprehensive collection of the known psychedelic phenethylamines and related compounds. There are 126 main compounds with detailed physical properties, synthesis and analytical chemistry, biochemistry, pharmacological properties, and legal status. Fully referenced with over 2,000 citations. There are sub-tables of lesser-studied structural homologues and analogues, over 1300 total compounds covered. GCMS scans are included for 229 compounds. This book is an invaluable resource for researchers, physicians, chemists, and law enforcement.

The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, door Alexander T. Shulgin, Tania Manning & Paul F. Daley, Transform Press, 811 pagina’s.

Koop dit boek via bookdepository.com en steun daarmee Stichting OPEN

The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations

Abstract

Background: Recent findings suggest that the serotonergic system and particularly the 5-HT2A/1A receptors are implicated in visual processing and possibly the pathophysiology of visual disturbances including hallucinations in schizophrenia and Parkinson’s disease.

Methods: To investigate the role of 5-HT2A/1A receptors in visual processing the effect of the hallucinogenic 5-HT2A/1A agonist psilocybin (125 and 250 μg/kg vs. placebo) on the spatiotemporal dynamics of modal object completion was assessed in normal volunteers (n = 17) using visual evoked potential recordings in conjunction with topographic-mapping and source analysis. These effects were then considered in relation to the subjective intensity of psilocybin-induced visual hallucinations quantified by psychometric measurement.

Results: Psilocybin dose-dependently decreased the N170 and, in contrast, slightly enhanced the P1 component selectively over occipital electrode sites. The decrease of the N170 was most apparent during the processing of incomplete object figures. Moreover, during the time period of the N170, the overall reduction of the activation in the right extrastriate and posterior parietal areas correlated positively with the intensity of visual hallucinations.

Conclusions: These results suggest a central role of the 5-HT2A/1A-receptors in the modulation of visual processing. Specifically, a reduced N170 component was identified as potentially reflecting a key process of 5-HT2A/1A receptor–mediated visual hallucinations and aberrant modal object completion potential.

Kometer, M., Cahn, B. R., Andel, D., Carter, O. L., & Vollenweider, F. X. (2011). The 5-HT2A/1A Agonist Psilocybin Disrupts Modal Object Completion Associated with Visual Hallucinations. Biological Psychiatry, 69, 399–406. http://dx.doi.org/10.1016/j.biopsych.2010.10.002
Link to full text

Start Your Own Religion: New York State’s Acid Churches

Abstract

This paper describes a radical and short-lived spiritual movement that emerged in New York State in the 1960s. With Dr. Timothy Leary as the figurehead, two of these psychedelic religions rose to brief cultural prominence in period of 1963–1968 when Leary and his communal group made their home in the small village of Millbrook, New York. Due to negative media attention and a subsequent law enforcement crackdown brought upon at least partially by the increasingly provocative stance of the leaders of these psychedelic groups, they were forced to flee the state by early 1968. This paper establishes the historical significance of New York State’s Acid Churches within the culture of the 1960s and draws the link to today’s Neopagan and New Age movements and the rebirth of the use of psychedelic substances within the modern scientific, psychological, and therapeutic communities.

Lander, D. R. (2011).  Start Your Own Religion: New York State’s Acid Churches. Nova Religio: The Journal of Alternative and Emergent Religions, 14(3), 64–80. http://dx.doi.org/10.1525/nr.2011.14.3.64
Link to full text

A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms?

Abstract

The Selva Pascuala mural, a work of post-Paleolithic rock art in Spain, contains fungoid figures herein hypothesized to depict neurotropic fungi, especially Psilocybe hispanica, a species that occurs in a neighboring region. This hypothesis is based on features of these figures related to fungal morphology, along with ethnographic analogy, and shamanistic explanations of rock art. If correct, this interpretation would support inference of prehistoric utilization of this fungus in the region. The mural represents the first direct evidence for possible ritual use of Psilocybe in prehistoric Europe.

Akers, B. P., Ruiz, J. F., Piper, A., & Ruck, C. A. P. (2011). A Prehistoric Mural in Spain Depicting Neurotropic Psilocybe Mushrooms?. Economic Botany, 65(2), 1–8. http://dx.doi.org/10.1007/s12231-011-9152-5
Link to full text

Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs

Abstract

Aims: In field studies assessing cognitive function in illicit ecstasy users, there are several frequent confounding factors that might plausibly bias the findings toward an overestimate of ecstasy-induced neurocognitive toxicity. We designed an investigation seeking to minimize these possible sources of bias.

Design: We compared illicit ecstasy users and non-users while (1) excluding individuals with significant life-time exposure to other illicit drugs or alcohol; (2) requiring that all participants be members of the ‘rave’ subculture; and (3) testing all participants with breath, urine and hair samples at the time of evaluation to exclude possible surreptitious substance use. We compared groups with adjustment for age, gender, race/ethnicity, family-of-origin variables and childhood history of conduct disorder and attention deficit hyperactivity disorder. We provide significance levels without correction for multiple comparisons.
Setting: Field study.
Participants: Fifty-two illicit ecstasy users and 59 non-users, aged 18–45 years.
Measurements: Battery of 15 neuropsychological tests tapping a range of cognitive functions.
Findings: We found little evidence of decreased cognitive performance in ecstasy users, save for poorer strategic self-regulation, possibly reflecting increased impulsivity. However, this finding might have reflected a pre-morbid attribute of ecstasy users, rather than a residual neurotoxic effect of the drug. Conclusions In a study designed to minimize limitations found in many prior investigations, we failed to demonstrate marked residual cognitive effects in ecstasy users. This finding contrasts with many previous findings—including our own—and emphasizes the need for continued caution in interpreting field studies of cognitive function in illicit ecstasy users.
Halpern, J. H., Sherwood, A. R., Hudson, J. I., Gruber, S. Kozin, D., & Pope Jr., H. G. (2011). “Residual neurocognitive features of long-term ecstasy users with minimal exposure to other drugs. Addiction, 106(4), 777-786. http://dx.doi.org/10.1111/j.1360-0443.2010.03252.x
Link to full text

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens

Abstract

Serotonergic hallucinogens produce profound changes in perception, mood, and cognition. These drugs include phenylalkylamines such as mescaline and 2,5-dimethoxy-4-methylamphetamine (DOM), and indoleamines such as (+)-lysergic acid diethylamide (LSD) and psilocybin. Despite their differences in chemical structure, the two classes of hallucinogens produce remarkably similar subjective effects in humans, and induce cross-tolerance. The phenylalkylamine hallucinogens are selective 5-HT(2) receptor agonists, whereas the indoleamines are relatively non-selective for serotonin (5-HT) receptors. There is extensive evidence, from both animal and human studies, that the characteristic effects of hallucinogens are mediated by interactions with the 5-HT(2A) receptor. Nevertheless, there is also evidence that interactions with other receptor sites contribute to the psychopharmacological and behavioral effects of the indoleamine hallucinogens. This article reviews the evidence demonstrating that the effects of indoleamine hallucinogens in a variety of animal behavioral paradigms are mediated by both 5-HT(2) and non-5-HT(2) receptors.

Halberstadt, A. L., & Geyer, M.A. (2011). Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 61(3), 364-381. http://dx.doi.org/10.1016/j.neuropharm.2011.01.017
Link to full text

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer

Abstract

Context: Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer.

Objective: To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive anxiety.

Design: A double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, with subjects acting as their own control, using a moderate dose (0.2 mg/kg) of psilocybin.

Setting: A clinical research unit within a large public sector academic medical center.

Participants: Twelve adults with advanced-stage cancer and anxiety.

Main Outcome Measures: In addition to monitoring safety and subjective experience before and during experimental treatment sessions, follow-up data including results from the Beck Depression Inventory, Profile of Mood States, and State-Trait Anxiety Inventory were collected unblinded for 6 months after treatment.

Results: Safe physiological and psychological responses were documented during treatment sessions. There were no clinically significant adverse events with psilocybin. The State-Trait Anxiety Inventory trait anxiety subscale demonstrated a significant reduction in anxiety at 1 and 3 months after treatment. The Beck Depression Inventory revealed an improvement of mood that reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with psilocybin that approached but did not reach significance.

Conclusions: This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety. Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field.

Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. Archives of General Psychiatry, 68(1), 71-78. http://dx.doi.org/10.1001/archgenpsychiatry.2010.116
Link to full text

interested in becoming a trained psychedelic-assisted therapist?

Indigenous Talk: Fulni-ô Culture & Jurema - Online Event - Dec 12th